Bio swiss pharma steroids

In January 2014, Novartis announced plans to cut 500 jobs from its pharmaceuticals division. [54] In February 2014, Novartis announced that it has acquired CoStim Pharmaceuticals. [55] In May 2014, Novartis bought the rights to market Ophthotech 's Fovista (an anti- PDGF aptamer , also being investigated for use in combination with anti- VEGF treatments) outside the United States for up to $1 billion. [56] Novartis will acquire exclusive rights to market the eye drug outside of America whilst retaining US marketing rights. The company agreed to pay Ophthotech $200 million upfront, and $130 million in milestone payments relating to Phase III trials. [56] Ophthotech is also eligible to receive up to $300 million dependent upon future marketing approval milestones outside of America and up to $400 million relating to sales milestones. [57] In September 2014, Ophthotech received its first $50 million phase III trial milestone payment from Novartis. [58] In April 2014, Novartis announced that it would acquire GlaxoSmithKline 's cancer drug business for $16 billion as well as selling its vaccines business to GlaxoSmithKline for $ billion. [59] In August 2014 Genetic Engineering & Biotechnology News reported that Novartis had acquired a 15% stake in Gamida Cell for $35 million, with the option to purchase the whole company for approximately $165 million. [60] In October 2014, Novartis announced its intention to sell its influenza vaccine business (inclusive of its development pipeline), subject to regulatory approval, to CSL for $275 million. [61]

Polymeric micelles represent a specific class of PLG-based drug-delivery nanoparticles, whereby a diblock of polylactide and polyethylene glycol (PEG) with hydrophobic and hydrophilic regions respectively allows for self-assembly of the polymer chains into 50-nm nanoparticles. The resulting core-shell constructs have PEG oriented on the surface. Moieties conjugated to the surface are used to target the nanoparticles to biological sites and to minimize toxicity. Genexol (paclitaxel) by Samyang is an example of a PLG polymeric micelle product on the market. Paclitaxol is encapsulated within the hydrophobic core of the polymeric micelle, and the product is indicated for the treatment of breast, lung, and ovarian cancers. The PLG polymeric micelle technology enhances the solubility of paclitaxel and allows significantly higher dosing of paclitaxel to patients without additional toxicity (15). 

Bio swiss pharma steroids

bio swiss pharma steroids

Media:



http://buy-steroids.org